145 related articles for article (PubMed ID: 25971265)
1. [Roles of mTORC1 in acute myeloid leukemia].
Hoshii T; Hirao A
Rinsho Ketsueki; 2015 Apr; 56(4):359-65. PubMed ID: 25971265
[TBL] [Abstract][Full Text] [Related]
2. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 is essential for leukemia propagation but not stem cell self-renewal.
Hoshii T; Tadokoro Y; Naka K; Ooshio T; Muraguchi T; Sugiyama N; Soga T; Araki K; Yamamura K; Hirao A
J Clin Invest; 2012 Jun; 122(6):2114-29. PubMed ID: 22622041
[TBL] [Abstract][Full Text] [Related]
4. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
5. Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.
Fang Y; Yang Y; Hua C; Xu S; Zhou M; Guo H; Wang N; Zhao X; Huang L; Yu F; Cheng H; Wang ML; Meng L; Cheng T; Yuan W; Ma D; Zhou J
Leukemia; 2017 Feb; 31(2):414-422. PubMed ID: 27499138
[TBL] [Abstract][Full Text] [Related]
6. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
Ghosh J; Kapur R
Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
[TBL] [Abstract][Full Text] [Related]
7. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.
Feng Y; Wu L
Biochem Biophys Res Commun; 2017 Feb; 483(2):897-903. PubMed ID: 28082200
[TBL] [Abstract][Full Text] [Related]
8. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
[TBL] [Abstract][Full Text] [Related]
9. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
[TBL] [Abstract][Full Text] [Related]
10. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
11. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 and mTORC2 have largely distinct functions in Purkinje cells.
Angliker N; Burri M; Zaichuk M; Fritschy JM; Rüegg MA
Eur J Neurosci; 2015 Oct; 42(8):2595-612. PubMed ID: 26296489
[TBL] [Abstract][Full Text] [Related]
13. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
[TBL] [Abstract][Full Text] [Related]
14. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
Kim WI; Matise I; Diers MD; Largaespada DA
Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
[TBL] [Abstract][Full Text] [Related]
15. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
16. Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia.
Schwarzer A; Holtmann H; Brugman M; Meyer J; Schauerte C; Zuber J; Steinemann D; Schlegelberger B; Li Z; Baum C
Oncogene; 2015 Jul; 34(27):3593-604. PubMed ID: 25241901
[TBL] [Abstract][Full Text] [Related]
17. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
[TBL] [Abstract][Full Text] [Related]
18. Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.
Sujobert P; Poulain L; Paubelle E; Zylbersztejn F; Grenier A; Lambert M; Townsend EC; Brusq JM; Nicodeme E; Decrooqc J; Nepstad I; Green AS; Mondesir J; Hospital MA; Jacque N; Christodoulou A; Desouza TA; Hermine O; Foretz M; Viollet B; Lacombe C; Mayeux P; Weinstock DM; Moura IC; Bouscary D; Tamburini J
Cell Rep; 2015 Jun; 11(9):1446-57. PubMed ID: 26004183
[TBL] [Abstract][Full Text] [Related]
19. Targeting translation in acute myeloid leukemia: a new paradigm for therapy?
Tamburini J; Green AS; Chapuis N; Bardet V; Lacombe C; Mayeux P; Bouscary D
Cell Cycle; 2009 Dec; 8(23):3893-9. PubMed ID: 19934662
[TBL] [Abstract][Full Text] [Related]
20. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
Muntean AG; Hess JL
Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
